Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Radziuk, J.
Right arrow Articles by Pye, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Radziuk, J.
Right arrow Articles by Pye, S.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 46, Issue 9 1406-1413, Copyright © 1997 by American Diabetes Association


ARTICLES

Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver

J Radziuk, Z Zhang, N Wiernsperger and S Pye
Ottawa Civic Hospital and the University of Ottawa, Ontario, Canada.

To directly assess the effects of the biguanide, metformin, on hepatic gluconeogenesis, it was added at high therapeutic levels (90 microg/ml) to the medium perfusing an isolated rat liver. Lactate (1 mg/min) was infused simultaneously along with [14C]lactate with or without [3H]lactate. [6-(3)H]glucose was added at the beginning of the perfusion in studies where [3H]lactate was not infused. Glucose levels decreased relative to control studies (metformin dose = 0) and lactate concentrations increased in this closed system. Quantitative analysis of the relationship between labeled glucose and lactate indicated that the flux of carbon from lactate to glucose and CO2 was halved, whereas reflux from glucose to lactate increased by approximately 80%. This was corroborated by measurement of labeled lactate extraction as well as glucose, CO2, and lactate production across the liver. Glycogen content of the liver fell by 60% relative to control and was greater for the gluconeogenic pathway. These data are consistent with an inhibitory action of metformin on gluconeogenesis, which is due to a primary inhibition of hepatic lactate uptake.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J EndocrinolHome page
J. Klein, S. Westphal, D. Kraus, B. Meier, N. Perwitz, V. Ott, M. Fasshauer, and H H. Klein
Metformin inhibits leptin secretion via a mitogen-activated protein kinase signalling pathway in brown adipocytes
J. Endocrinol., November 1, 2004; 183(2): 299 - 307.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
C. Bouche, S. Serdy, C. R. Kahn, and A. B. Goldfine
The Cellular Fate of Glucose and Its Relevance in Type 2 Diabetes
Endocr. Rev., October 1, 2004; 25(5): 807 - 830.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
B. Brunmair, K. Staniek, F. Gras, N. Scharf, A. Althaym, R. Clara, M. Roden, E. Gnaiger, H. Nohl, W. Waldhausl, et al.
Thiazolidinediones, Like Metformin, Inhibit Respiratory Complex I: A Common Mechanism Contributing to Their Antidiabetic Actions?
Diabetes, April 1, 2004; 53(4): 1052 - 1059.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
H. J. Woerle, C. Meyer, E. M. Popa, P. E. Cryer, and J. E. Gerich
Renal Compensation for Impaired Hepatic Glucose Release During Hypoglycemia in Type 2 Diabetes: Further Evidence for Hepatorenal Reciprocity
Diabetes, June 1, 2003; 52(6): 1386 - 1392.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
L. A. Stadtmauer, B. C. Wong, and S. Oehninger
Should patients with polycystic ovary syndrome be treated with metformin?: Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction
Hum. Reprod., December 1, 2002; 17(12): 3016 - 3026.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
L. Meyer, P. Bohme, I. Delbachian, P. Lehert, N. Cugnardey, P. Drouin, and B. Guerci
The Benefits of Metformin Therapy During Continuous Subcutaneous Insulin Infusion Treatment of Type 1 Diabetic Patients
Diabetes Care, December 1, 2002; 25(12): 2153 - 2158.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
D. Kirpichnikov, S. I. McFarlane, and J. R. Sowers
Metformin: An Update
Ann Intern Med, July 2, 2002; 137(1): 25 - 33.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
G. Mithieux, L. Guignot, J.-C. Bordet, and N. Wiernsperger
Intrahepatic Mechanisms Underlying the Effect of Metformin in Decreasing Basal Glucose Production in Rats Fed a High-Fat Diet
Diabetes, January 1, 2002; 51(1): 139 - 143.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
Z. Zhang and J. Radziuk
Inverse relationship between peripheral insulin removal and action: studies with metformin
Am J Physiol Endocrinol Metab, December 1, 2001; 281(6): E1240 - E1248.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
S. Song, S. Andrikopoulos, C. Filippis, A. W. Thorburn, D. Khan, and J. Proietto
Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin
Am J Physiol Endocrinol Metab, August 1, 2001; 281(2): E275 - E282.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1997 by the American Diabetes Association.